The generic drugs market is estimated to have reached $257.3bn in 2018 and is expected to grow at a CAGR of 8.8% in the first half of the forecast period. Asia-Pacific held 31% of the generic drugs market in 2018.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 246-page report you will receive 66 tables and 84 figures– all unavailable elsewhere.
The 246-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Generic Drugs Market forecasts from 2019-2029
• Generic Drugs Market forecasts from 2019-2029 by Regional and National Market:
• North America: U.S., Canada
• Europe: Germany, France, UK, Italy, Spain, Rest of Europe
• Asia-Pacific: Japan, China, Australia, South Korea, India, Rest of Asia-Pacific
• Middle East & Africa: South Africa, Saudi Arabia, UAE, Rest of Middle east & Africa
• Latin America: Brazil, Argentina, Mexico, Rest of Latin America
• Profiles and generic drugs revenue forecasts from 2019-2029 of these selected leading companies:
• Abbott
• Apotex
• Aspen
• Dr. Reddy’s Laboratories Limited
• Fresenius Kabi
• Mylan
• Novartis
• Pfizer
• Sanofi
• Sun Pharma
• Teva
• Qualitative analysis of the generic drugs market:
• SWOT Analysis of the generic drugs market
• Porter’s Five Forces Analysis of the generic drugs market
• Discussion on factors that drive and restrain the generic drugs market
• Key Questions Answered by This Report:
• How is the global market for generic drugs evolving?
• What are the major factors driving and restraining the generic drugs market dynamics?
• What were the market shares of the leading national markets in the global generic drugs market in 2018?
• How will each of these national markets grow over the forecast period and how much revenue will these markets account for by 2029?
• How will the market shares for each of the national markets develop from 2018 to 2029?
• Which particular national markets will be the main drivers of growth in the global market for generics from 2018 to 2029?
• How will political and regulatory factors influence the regional markets and submarkets?
• What are the predictions for partnerships, consolidation for existing players and the potential prospects for new market entrants?
• How will the industry sector evolve as legislations around patents and patent expiries change during the period between 2018 and 2029?
Visiongain’s study is intended for anyone requiring commercial analyses for the Generic Drugs Market. You find data, trends and predictions.
Buy our report today Global Generic Drugs Market Analysis : Forecast From 2019-2029 Growth in Leading Regional and National Markets – North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America, US, Canada, Germany, France, UK, Italy, Spain, India, China, Australia, South Korea, Japan, South Africa, Saudi Arabia, U.A.E, Brazil, Argentina, Mexico, Teva, Novartis, Mylan, Pfizer, Abbott, Sun Pharma, Aspen, Fresenius Kabi, Sanofi, Dr. Reddy’s Laboratories Limited, Apotex.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Global Generic Drugs: Market Overview
1.2 Global Generic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is this Report for?
1.7 Methodology
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. An Introduction to Generic Drugs
2.1 An Introduction to the Rise of Generic Drugs
2.2 What Are Generic Drugs?
2.2.1 Generic Active Ingredients
2.3 A Brief Overview of the Pharmaceutical Industry
2.3.1 Brief History of Generic Drugs
2.3.2 The Hatch-Waxman Act: The Rise of Generics
2.4 Demonstrating Bioequivalence: A Major Factor in Approving Generics
2.5 Types of Generics – Authorised, Branded and Unbranded
2.6 Complex Generics
2.7 Classification of Generic Drugs Markets
2.8 Is Generic Substitution Bad News for Big Pharma Business?
2.8.1 The 'Ever greening' of Pharmaceutical Products
2.9 Regulation of Generic Drugs
2.9.1 Regulation in the US
2.9.1.1 Obtaining FDA Approval: NDAs and ANDAs
2.9.1.2 The Hatch-Waxman Act Title I: Promotion of Generic Drugs
2.9.1.3 The Hatch-Waxman Act Title II: Incentives for the Branded Industry
2.9.1.4 How Hatch-Waxman Act Impacted the US Pharmaceuticals Market?
2.9.1.5 How Market Entry Timing Influences Product Success
2.9.2 Regulation in Europe
2.9.2.1 EU Marketing Approval Procedures
2.9.2.2 The 8+2+1 Rule: EU Data Exclusivity
2.9.2.3 Supplementary Protection Certificates
2.9.2.4 Variation in Drug Development Regulations between European Countries
2.9.2.5 The Move towards Harmonisation of Standards
2.9.2.6 The Impact of Europe’s Unitary Patent System on Generic Drugs
2.9.2.7 In or Out: Unitary Patent Strategy for European Generic Drug Manufacturing
2.9.3 Regulation in Japan
2.9.4 Regulation in China
2.10 Compulsory Licensing
2.11 Market Definition and Scope of this Report
2.11.1 Market Sizing and Revenue Reporting
3. Generic Drugs Market Forecast 2019-2029
3.1 The Global Generic Drugs Market: Market Overview
3.1.1 Segmenting the Global Generic Drugs Market
3.2 The Rise of the Global Generic Drugs Market in 2019
3.3 The Global Generic Drugs Market: Sales Forecast 2019-2029
3.4 Generic Drugs: Regional Market Forecast: 2019-2029
3.4.1 Changes in Generic Drug Regional Market Shares 2019-2029
3.5 National Markets that Will Drive Generic Drugs Growth
3.6 Changes in Market Shares by National Market 2019-2029
3.7 Drivers and Restraints for the Global Generic Drugs Market 2019-2029
4. North America Generic Drugs Market, 2019-2029
4.1 Generic Drugs in the North America: Market Overview
4.1.1 The Hatch-Waxman Act and Its Ongoing Effects
4.1.2 Consolidation in the Drug Development and Supply Chain Driving North America Generics
4.2 North America Generic Drugs Market: Drivers and Restraints 2019-2029
4.3 North America Generic Drugs Market Forecast: 2019-2029
4.4 Leading Companies Operating within the North America Generic Drugs Market
4.4.1 Increasing Acceptance of Generics amongst Consumers
4.4.2 Affordable Care Act: Expanding Medicare Coverage
4.5 North America Generic Drugs Market – Strategic Analysis
4.5.1 Will Biosimilars Dictate the Future of the US Generics Market?
4.5.2 The Backlog of ANDA Applications
4.5.3 The Generic Drug User Fee Amendments (GDUFA)
4.5.4 Shortages of Generic Drugs Will Restrain the Market
4.5.5 The Anti-Competitive ‘Pay for Delay’ Effect
4.6 US Generic Drugs Market: A Range of Factors Contributing to Growth
4.7 Canada Generic Drugs Market: A Range of Factors Contributing to Growth
4.8 North America Generic Drugs Market: Market Share Analysis
5. Europe Generic Drugs Market, 2019-2029
5.1 Generic Drugs in the Europe: Market Overview
5.1.1 Why Growth in Some Markets is Being Hindered?
5.1.2 Predominant Pricing Systems and Generic Penetration in European Markets
5.1.2.1 Lower Patient Co-Payments Drive Demand for Generics
5.1.2.2 The Effects of Tendering for Generic Medicines
5.1.3 Will Europe Move towards Free-Pricing Systems?
5.1.4 Challenges in the European Regulatory Environment
5.1.5 Ending Anti-Competitive ‘Pay for Delay’ Tactics in Europe
5.1.6 FDA and EMA Joint Data Sharing and Inspections
5.2 Europe Generic Drugs Market Forecast: 2019-2029
5.3 Germany Generic Drugs Market: New Reforms to Medicinal Pricing May Impact Market Entry
5.4 UK Generic Drugs Market: A Mature Market with Growth Potentials
5.4.1 Cost Pressures and Demand-Side Policies Drive UK Generic Penetration
5.5 France Generic Drugs Market: Healthcare Reforms Impacting on Market Growth
5.6 Italy Generic Drugs Market: Branded Generics Hindering Overall Growth
5.6.1 The Tightening of Italy’s Patent Legislations
5.6.2 The Italian Healthcare System – A Tale of Falling Budgets
5.7 Spain Generic Drugs Market: Room for Growth
5.7.1 Cost-Containment Measures Helping to Boost Generic Drug Use
5.8 Europe Generic Drugs Market: Market Share Analysis
6 Asia-Pacific Generic Drugs Market, 2019-2029
6.1 Generic Drugs in the Asia-Pacific Market: Market Overview
6.2 Indian Generic Drugs Market: Regulatory Failures Hindering Sales Growth
6.2.1 Leading Companies in the Indian Generic Drugs Market
6.2.2 Indian Generic Drugs Market: Sales Forecast 2019-2029
6.2.3 The Reforms to India’s Drug Prices Control Order and Its Likely Effects on Generic Drugs Revenues
6.2.4 Expansion of the National Healthcare Coverage Increases the Need for Generics
6.2.5 Has Recent Manufacturing Quality Failures Dented India’s Generics Growth?
6.3 Chinese Generic Drugs Market: Domestic Companies Dominate the Market Landscape
6.3.1 The Major Drivers of Growth in the Chinese Generics Market
6.3.2 Chinese Generic Drugs Market: Sales Forecast 2019-2029
6.3.3 Compulsory Licensing of Generic Drugs
6.3.4 Expansion of Healthcare Coverage and Reimbursement
6.3.5 The Impacts of Price Controls and the Anhui Model
6.4 Japanese Generic Drugs Market: High Barriers to Entry
6.4.1 Public Perception of Generics in Japan
6.4.2 Japanese Generic Drugs Market: Leading Companies
6.4.3 Government Initiatives Driving Generic Penetration
6.4.4 Japanese Attitudes to Generic Drugs
6.4.5 Japanese Generic Drugs Market: Sales Forecast 2019-2029
6.5 Australia Generic Drugs Market: Increased Market Access Supports the Market Growth
6.5.1 Australia Generic Drugs Market: Sales Forecast 2019-2029
6.6 South Korean Generic Drugs Market: Expected to Continue Its Trend of Growth
6.6.1 Pharmaceutical Price Controls and Measures Being Implemented in South Korea
6.6.2 KORUS FTA: The Free Trade Agreement between South Korea and the US
6.6.3 The Free Trade Agreement between Korea and the European Union
6.6.4 South Korean Generic Drugs Market: Sales Forecast 2019-2029
6.7 Asia-Pacific Generic Drugs Market: Market Share Analysis
7 Middle East & Africa Generic Drugs Market, 2019-2029
7.1 Generic Drugs in the Middle East & Africa Market: Market Overview
7.2 South Africa Generic Drugs Market:
7.2.1 South Africa Generic Drugs Market: Sales Forecast 2019-2029
7.3 Saudi Arabia Generic Drugs Market:
7.3.1 Saudi Arabia Generic Drugs Market: Sales Forecast 2019-2029
7.4 UAE Generic Drugs Market:
7.4.1 UAE Generic Drugs Market: Sales Forecast 2019-2029
7.5 Middle East & Africa Generic Drugs Market: Market Share Analysis
8. Latin America Generic Drugs Market, 2019-2029
8.1 Generic Drugs in the Latin American Market: Market Overview
8.2 Brazil Generic Drugs Market:
8.2.1 Brazil Generic Drugs Market: Sales Forecast 2019-2029
8.3 Argentina Generic Drugs Market:
8.3.1 Argentina Generic Drugs Market: Sales Forecast 2019-2029
8.4 Mexico Generic Drugs Market:
8.4.1 Mexico Generic Drugs Market: Sales Forecast 2019-2029
8.5 Latin America Generic Drugs Market: Market Share Analysis
9 Leading Companies in the Generic Drugs Market
9.1 Generic Drugs: Continuous Expansion to Rival
9.1.1 The Leading Companies in the Global Generics Market
9.2 Teva Pharmaceuticals Industries Limited
9.2.1 Teva: Historical Financial and Performance Analysis, 2014-2018
9.2.2 Teva Generic Drugs Sales Forecast 2019-2029
9.2.3 Teva acquired Allergan’s Generic Business Segment – Actavis Generic
9.2.3.1 Further Entry into the Japanese Generics Market
9.2.4 Teva: Generic Drugs Portfolio Analysis
9.2.4.1 High-Value Generics to Drive Teva’s Generics Growth?
9.2.4.2 The Shift towards Innovation
9.2.4.3 Copaxone Leads Teva’s Moving Focus
9.2.4.4 The Threat of Generic Erosion to Teva’s Products
9.2.4.5 Teva: What Future Moves Could We Expect?
9.3 Novartis
9.3.1 Novartis/Sandoz: Historical Financial and Performance Analysis, 2014-2018
9.3.2 Novartis/Sandoz Generic Drugs Sales Forecast 2019-2029
9.3.3 Novartis/Sandoz Generic Drugs Portfolio Analysis, 2017-2018
9.3.3.1 Emphasis on Difficult-to-Manufacture Products
9.3.3.2 What Does the Future Hold for Novartis’ Generic Drugs Business
9.4 Mylan
9.4.1 Mylan: Historical Financial and Performance Analysis, 2012-2018
9.4.2 Mylan Generic Drugs Sales Forecast 2019-2029
9.4.3 Mylan: Recent Developments
9.4.3.1 Acquisition of Meda AB
9.4.3.2 Acquisition of Abbott’s Generic Business
9.4.3.3 Mylan’s Growth in Manufacturing Capacity
9.4.3.4 Mylan Acquires Rights to GSK’s Advair, Diskus and Seretide
9.4.3.5 The Race to Market Copaxone Generics
9.4.3.6 Strategic Acquisition of Agila Expands Mylan’s Injectables Business
9.4.4 Mylan’s Collaborative Efforts
9.4.4.1 Biosimilar Collaboration with India’s Biocon
9.4.4.2 Biosimilar Collaborations with Momenta
9.4.4.3 What Does the Future Hold for Mylan’s Generic Drugs Business?
9.5 Pfizer
9.5.1 Pfizer: Historical Financial and Performance Analysis, 2014-2016
9.5.2 Pfizer’s Restructuring Strategy
9.5.3 Pfizer’s Done Deal with Hospira
9.5.4 Pfizer Generic Drugs Sales Forecast 2019-2029
9.5.5 Hospira: A Brief Overview of Operations
9.5.6 Hospira: Historical Financial and Performance Analysis 2011-2015
9.5.7 Hospira: Recent Developments
9.5.7.1 Hospira’s Expansion through Strategic Acquisitions
9.5.7.2 Hospira: Manufacturing Concerns and Remediation Efforts
9.5.8 Future Prospects for Pfizer’s Generic Business
9.5.8.1 The Pfizer-Allergan Deal Falls Through
9.5.8.2 Activities of Allergan (Actavis) Prior to Mega-Merger
9.5.8.3 Actavis’ Work on Biosimilars
9.6 Abbott
9.6.1 Abbott: Historical Financial and Performance Analysis, 2014-2016
9.6.2 Abbott Generic Drugs Sales Forecast 2019-2029
9.6.3 Abbott: Recent Developments
9.6.3.1 Abbott acquired St. Jude Medical
9.6.3.2 Abbott after the Spin-Off of AbbVie - The Established Products Business Segment
9.6.3.3 Acquisition of Solvay Pharmaceuticals and Piramal Healthcare Solutions
9.6.3.4 Acquisition of CFR Pharmaceuticals Opens New Markets
9.6.4 What Does the Future Hold for Abbott’s Generic Drugs Business?
9.7 Sun Pharma
9.7.1 Sun Pharma’s Business Areas
9.7.2 Sun Pharma: Historical Financial and Performance Analysis, 2014-2018
9.7.3 Sun Pharma Generic Drugs Sales Forecast 2019-2029
9.7.4 Sun Pharma-Ranbaxy Acquisition
9.8 Aspen
9.8.1 Aspen: Historical Financial and Performance Analysis, 2014-2018
9.8.2 Aspen Generic Sales Forecast 2019-2029
9.8.3 Aspen: Recent Developments
9.8.3.1 Aspen Acquires Merck MSD’s Dutch API Plant
9.8.3.2 Acquisition of GSK’s Anti-Thrombosis Brands
9.8.3.3 Future Outlook for Aspen’s Generic Business
9.9 Fresenius Kabi
9.9.1 Fresenius Kabi: Historical Financial and Performance Analysis, 2014-201
9.9.2 Fresenius Kabi Generic Drugs Sales Forecast 2019-2029
9.9.3 InnoPharma Licensing Deal Bolsters Portfolio Grown Via Past Acquisition
9.9.4 Fresenius Kabi’s Joint Venture with PT Soho Global Health
9.9.5 Future Prospects for Fresenius Kabi’s Generics Business
9.10 Sanofi
9.10.1 Sanofi: Historical Financial and Performance Analysis, 2014-2018
9.10.2 Sanofi Generic Sales Forecast 2019-2029
9.10.3 Sanofi’s Response to Lantus Competition
9.10.4 Emerging Market Acquisitions
9.10.5 Future Prospects for Sanofi’s Generics Business
9.11 Dr. Reddy’s Laboratories Limited
9.11.1 Dr. Reddy’s: Historical Financial and Performance Analysis, 2015-2017
9.11.2 Dr. Reddy’s Generic Sales Forecast 2019-2029
9.11.3 Dr. Reddy’s launched generic Azacitidine for Injection in the Canadian Market
9.11.4 The company acquired Imperial Credit Private Limited, a Non-Banking Finance Company
9.11.5 Dr. Reddy’s expanded its operations in the European region
9.12 Apotex, Inc.
9.12.1 Apotex expanded its manufacturing facilities in the U.S.
9.12.2 Apotex launched first Generic Version of Merck's Nasonex
10. Qualitative Analysis of the Generic Drugs Market
10.1 Market Factors Influencing the Global Generic Drugs Market
10.2 SWOT Analysis of the Global Generic Drugs Market
10.2.1 Strengths
10.2.1.1 Improving Clarity around Regulatory Processes
10.2.1.2 The Continuous Government Support for Generic Manufacturers – Precursors for Innovation
10.2.1.3 Higher Pace of Growth Compared with Innovative Pharma
10.2.1.4 Globalisation and Its Impact on Manufacturing Capabilities
10.2.2 Weaknesses
10.2.2.1 Safety and Quality Concerns in the Manufacturing Process
10.2.2.2 The Non-Uniformity of Excipients
10.2.2.3 The Uncertainty around Patent Extensions and Exclusivities
10.2.2.4 Sceptical Physicians and the Negative Consumer Perception of Generics
10.2.2.5 Inefficiencies in Certain Regulatory Approval Processes
10.2.3 Opportunities
10.2.3.1 Higher Value Biosimilars and Branded Generics
10.2.3.2 Patent Expiries Creating Opportunities
10.2.3.3 Changing Socio-Economic Conditions Impacting Generic Drugs Demand
10.2.3.4 Emerging Markets – Expected to Drive Generics Volume Growth over Time
10.2.4 Threats
10.2.4.1 Government Cost-Cutting Initiatives Impacting on Generic Drugs Prices
10.2.4.2 The Complexity Surrounding Patents and Patent Expiries
10.2.4.3 Pharmacies and Healthcare Payer Consolidations
10.2.4.4 Possible Impacts of a Declining Patent Pool
10.3 Porter’s Five Force Analysis of the Global Generic Drugs Market
10.3.1 Power of Buyers: Medium
10.3.2 Power of Suppliers: Low
10.3.3 Rivalry among Competitors: High
10.3.4 Threat of New Entrants: High
10.3.5 Threat of Substitutes: Low
11. Conclusion
11.1 Overview of Current Market Conditions and Market Forecast, 2019-2029
11.2 Generic Drugs as a Strategic Tool in Healthcare
11.3 Major Drivers of Growth for Generic Drugs
11.4 The Regulatory Landscape for Generic Drugs
11.5 Leading Generic Drug Manufacturers
11.6 Future Outlook for the Leading Regions within the Global Generic Drugs Market, 2019-2029
11.7 What Does the Future Hold for the Global Generic Drugs Market?
Appendices
Glossary
Some Associated Reports
Visiongain Report Sales Order Form
About Visiongain
List of Tables
Table 2.1 Types of Drug Names, 2018
Table 3.1 The Global Generic Drugs Market Size: Revenue ($bn) and Market Share (%) by Regional and National Markets, 2018 and 2019
Table 3.2 The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 3.3 The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2018-2029
Table 3.4 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2018, 2023, and 2029
Table 3.5 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2018-2023, 2023-2029, 2018-2029
Table 3.6 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2018, 2023, and 2029
Table 4.1 North America Generic Drugs Market: by Country Value ($bn), AGR (%), and CAGR (%), 2018 – 2029
Table 4.2 U.S. Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2018 – 2029
Table 4.3 Canada Generic Drugs Market Value ($bn), AGR (%), CAGR (%), 2018 – 2029
Table 5.1 Europe Generic Drugs Market: by Country Value ($bn), AGR (%) and CAGR (%) 2018- 2029
Table 5.2 Germany Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2018 – 2029
Table 5.3 U.K. Generic Drugs Market Value ($bn) and AGR (%) 2018 – 2029
Table 5.4 France Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2018 – 2029
Table 5.5 Italy Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2018 – 2029
Table 5.6 Spain Generic Drugs Market Value ($bn), AGR (%), and CAGR (%), 2018 – 2029
Table 6.1 India Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 6.2 Leading Drug Types in Indian Pharmaceutical Market: Revenue ($bn) and Market Share (%), 2018, 2023 & 2029
Table 6.3 China Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 6.4 Japan Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 6.5 Australia Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 6.6 South Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 7.1 South Africa Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 7.2 Saudi Arabia Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 7.3 UAE Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 8.1 Brazil Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 8.2 Argentina Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 8.3 Mexico Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 9.1 Top Generic Drugs Manufacturers: Total Revenue ($bn), Generic Drugs Revenue ($bn) and Generic Share of Revenue (%), 2017 and 2018
Table 9.2 Teva: Company Overview
Table 9.3 Teva: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2018
Table 9.4 Teva Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 9.5 Novartis: Overview
Table 9.6 Novartis/Sandoz: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2018
Table 9.7 Novartis/Sandoz Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 9.8 Mylan: Company Overview
Table 9.9 Mylan: Historical Generic Drugs Sales ($bn) and AGR (%), 2012-2018
Table 9.10 Mylan: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 9.11 Pfizer: Company Overview
Table 9.12 Pfizer (Greenstone): Historical ‘Established Products’ Drugs Sales ($bn) and AGR (%), 2014-2018
Table 9.13 Pfizer: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 9.14 Hospira: Company Overview
Table 9.15 Hospira: Historical Specialty Injectables Sales ($bn) and AGR (%), 2011-2015
Table 9.16 Abbott: Company Overview
Table 9.17 Abbott: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2018
Table 9.18 Abbott: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 9.19 Sun Pharmaceuticals: Company Overview
Table 9.20 Sun Pharma: Historical Generic Drugs Sales ($bn), 2014-2018
Table 9.21 Sun Pharma Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 9.22 Aspen: Company Overview
Table 9.23 Aspen: Historical Revenue ($bn, bn Rand) and AGR (%), 2014-2018
Table 9.24 Aspen Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 9.25 Fresenius Kabi: Company Overview
Table 9.26 Fresenius Kabi: Historical Generic Drugs Sales ($bn), 2014-2018
Table 9.27 Fresenius Kabi: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 9.28 Sanofi: Company Overview
Table 9.29 Sanofi: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2018
Table 9.30 Sanofi Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
Table 9.31 Dr. Reddy’s Laboratories Limited: Company Overview
Table 9.32 Dr. Reddy’s: Historical Generic Drugs Sales ($bn) and AGR (%), 2015-2017
Table 9.33 Dr. Reddy’s Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2029
Table 9.34 Apotex, Inc.: Company Overview
Table 10.1 SWOT Analysis of the Generic Drugs Market
Table 11.1 Global Generic Drugs Market Forecast: Revenue ($bn) and CAGR (%), 2018, 2023 and 2029
Table 11.2 Top Generic Drug Manufacturers: Generic Drugs Revenue ($bn) and Market Share (%), 2018
Table 11.3 Global Generic Drugs Market Forecast: Revenue ($bn) by Regional Markets, 2018, 2023 and 2029
List of Figures
Figure 1.1 Global Generic Drugs Market Segmentation
Figure 2.1 EU Data Exclusivity for Generics: Possible Scenarios, 2018
Figure 3.1 The Global Generic Drugs Market Size: Revenue ($bn) by Regional Markets, 2018
Figure 3.2 The Global Generic Drugs Market Size: Revenue ($bn) by Regional Markets, 2023
Figure 3.3 The Global Generic Drugs Market Size: Revenue ($bn) by National Markets, 2018
Figure 3.4 The Global Generic Drugs Market Size: Revenue ($bn) by National Markets, 2023
Figure 3.5 Global Generic Drugs Market Forecast: ($bn) and AGR (%), 2018-2029
Figure 3.6 The Global Generic Drugs Market: Market Share (%) by Region, 2018
Figure 3.7 The Global Generic Drugs Market: Market Share (%) by Region, 2023
Figure 3.8 The Global Generic Drugs Market: Market Share (%) by Region, 2029
Figure 3.9 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2018-2023
Figure 3.10 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2023-2029
Figure 3.11 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2018-2029
Figure 3.12 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2018
Figure 3.13 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2023
Figure 3.14 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2029
Figure 3.15 The Global Generic Drugs Market Drivers & Restraints
Figure 4.1 North America Generic Drugs Market Drivers and Restraints
Figure 4.2 North America Generic Drugs Market: by Country Value ($bn) and AGR (%) 2018 – 2029
Figure 4.3 U.S. Generic Drugs Market Value ($bn) and AGR (%) 2018 – 2029
Figure 4.4 Canada Generic Drugs Market Value ($bn) and AGR (%) 2018 – 2029
Figure 4.5 North America Generic Drugs Market, % Country Share, 2018
Figure 4.6 North America Generic Drugs Market, % Country Share, 2023
Figure 4.7 North America Generic Drugs Market, % Country Share, 2029
Figure 5.1 Europe Generic Drugs Market: by Country Value ($ bn) and AGR (%) 2018 – 2029
Figure 5.2 Germany Generic Drugs Market Value ($bn) and AGR (%) 2018 – 2029
Figure 5.3 UK Generic Drugs Market Value ($bn) and AGR (%) 2018 – 2029
Figure 5.4 France Generic Drugs Market Value ($bn) and AGR (%) 2018 – 2029
Figure 5.5 Italy Generic Drugs Market Value ($bn) and AGR (%) 2018 – 2029
Figure 5.6 Spain Generic Drugs Market Value ($bn) and AGR (%) 2018 – 2029
Figure 5.7 Europe Generic Drugs Market, % Country Share, 2018
Figure 5.8 Europe Generic Drugs Market, % Country Share, 2023
Figure 5.9 Europe Generic Drugs Market, % Country Share, 2029
Figure 6.1 Asia-Pacific Generic Drugs Market Forecast: Revenue ($bn), 2018-2029
Figure 6.2 India Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.3 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2018
Figure 6.4 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2023
Figure 6.5 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2029
Figure 6.6 China Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.7 Japan Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.8 Australia Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 6.9 South Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 6.10 Asia-Pacific Generic Drugs Market, % Country Share, 2018
Figure 6.11 Asia-Pacific Generic Drugs Market, % Country Share, 2023
Figure 6.12 Asia-Pacific Generic Drugs Market, % Country Share, 2029
Figure 7.1 Middle East & Africa Generic Drugs Market Forecast: Revenue ($bn), 2018-2029
Figure 7.2 South Africa Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 7.3 Saudi Arabia Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 7.4 UAE Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 7.5 Middle East & Africa Generic Drugs Market, % Country Share, 2018
Figure 7.6 Middle East & Africa Generic Drugs Market, % Country Share, 2023
Figure 7.7 Middle East & Africa Generic Drugs Market, % Country Share, 2029
Figure 8.1 Latin America Generic Drugs Market Forecast: Revenue ($bn), 2018-2029
Figure 8.2 Brazil Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 8.3 Argentina Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 8.4 Mexico Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 8.5 Latin America Generic Drugs Market, % Country Share, 2018
Figure 8.6 Latin America Generic Drugs Market, % Country Share, 2023
Figure 8.7 Latin America Generic Drugs Market, % Country Share, 2029
Figure 9.1 Top Generic Drugs Manufacturers: Generic Drugs Revenue ($bn), 2017
Figure 9.2 Top Generic Drugs Manufacturers: Generic Drugs Revenue ($bn), 2018
Figure 9.3 Teva: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2018
Figure 9.4 Teva Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 9.5 Novartis/Sandoz: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2018
Figure 9.6 Novartis/Sandoz Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 9.7 Mylan: Historical Generic Drugs Sales ($bn) and AGR (%), 2012-2018
Figure 9.8 Mylan: Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 9.9 Pfizer: Historical ‘Established Products’ Drugs Sales ($bn) and AGR (%), 2014-2018
Figure 9.10 Pfizer Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 9.11 Hospira: Historical Specialty Injectables Sales ($bn) and AGR (%), 2011-2015
Figure 9.12 Abbott: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2018
Figure 9.13 Abbott Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 9.14 Sun Pharma: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2018
Figure 9.15 Sun Pharma Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 9.16 Aspen: Historical Revenue ($bn) and AGR (%), 2014-2018
Figure 9.17 Aspen: Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 9.18 Fresenius Kabi: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2018
Figure 9.19 Fresenius Kabi Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 9.20 Sanofi: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2018
Figure 9.21 Sanofi Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 9.22 Dr. Reddy’s: Historical Generic Drugs Sales ($bn) and AGR (%), 2015-2017
Figure 9.23 Dr. Reddy’s Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2016-2029
Figure 10.1 Porter’s Five Force Analysis of the Global Generic Drugs Market, 2018
Figure 11.1 Global Generic Drugs Market Forecast: Revenue ($bn), 2018, 2023 and 2029
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
